Skip to main content

Skytrofa

Generic: Lonapegsomatropin-tcgd

Verified·Oct 26, 2026
Manufacturer
Ascendis
NDC
73362-003
RxCUI
2569603
Route
SUBCUTANEOUS
ICD-10 indication
E23.0

Affordability Check

How much will you actually pay for Skytrofa?

In 30 seconds, see every legitimate way to afford Skytrofa — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Skytrofa

What is this medication?

Skytrofa is a prescription medicine used to treat growth failure in children one year of age and older who weigh at least 11.5 kilograms and do not produce enough growth hormone. This condition is medically known as growth hormone deficiency. The active ingredient in this medication is lonapegsomatropin-tcgd, which acts as a long-acting prodrug of somatropin to help stimulate physical growth and bone development.

This medication is specifically designed to be administered as a subcutaneous injection once per week, offering a less frequent alternative to traditional daily growth hormone injections. It works by slowly releasing human growth hormone into the bloodstream over the course of seven days. This sustained release helps pediatric patients maintain more consistent hormone levels to support their growth goals throughout the week.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Qualifying commercially insured patients
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Skytrofa appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

0%

16 of 5,499 plans

Most common tier

Tier 5

On 75% of covering formularies

Prior authorization required

100%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)2
17%
Tier 2 (generic)1
8%
Tier 5 (specialty)9
75%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 12 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.